HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test.

A new genotyping-based DNA assay (Digene LQ(®)) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease. The study population comprised 376 ASCUS women. The women were all Hybrid Capture II (HCII) positive and were admitted in three European referral gynecology clinics between 2007 and 2010. A colposcopy with histological examination was performed in all these patients. HPV 16 was typed in 40 % of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and 18 % of patients had mixed genotypes. Patients aged over 30 more often had the HPV 16 genotype than patients aged under 30 (29 % vs. 11 %, chi-square test p < 0.001). The risk of cervical intra-epithelial neoplasia of grade 2 or more (CIN2 +) when HPV 18 positive is lower than the probability associated with HPV 16 or HPV 31: 28 % vs. 58 % and 52 %, respectively (chi-square test, p = 0.005 and p = 0.05, respectively). The Digene LQ(®), a new sequence-specific hybrid capture sample preparation, is fast and efficient and allows high-throughput genotyping of 18 HR HPV types by PCR compared to traditional non-sequence-specific sample preparation methods.

Low prevalence of hepatitis E infection among pregnant women in Madrid, Spain.

Hepatitis E virus, a cause of sporadic hepatitis in developed countries is present in Spain. The aims of this study were to determine whether the prevalence of IgG anti-hepatitis E virus antibodies has increased in recent years in Spain and the prevalence in a study population at risk of developing the disease following the infection. Serum samples from 1,040 women in the first trimester of pregnancy were studied. The prevalence rate of 3.6% has not increased significantly since 1999 in spite of the large number of immigrants from endemic regions. IgM anti-HEV antibodies were detected in 0.67% of the patients suggesting that although subclinical infection exists the prevalence is very low. The reasons for the differences in the morbidity of HEV in pregnant women in different geographical areas remain unclear. Good hygienic measures and public health conditions are important factors for ensuring low prevalence of hepatitis E in Spain.

Detection of high-risk human papillomavirus by two molecular techniques: hybrid capture and linear array.

A number of human papillomaviruses (HPV) are the etiological agents of cervical cancer. The present study compared the performance of the hybrid capture method with that of linear array for the detection of high-risk HPV in 218 cervical samples. For the linear array technique, the DNA was extracted using two different procedures, one manual and the other automated. There was no difference in high-risk HPV (HR-HPV) detectability between the two extraction procedures but the automated procedure had the advantages of simplicity, time and efficiency. There was agreement in 199 (91.3%) of the results. The K value for the two assays was 0.81 indicative of "near perfect" agreement. Both methods, hybrid capture and linear array, are sensitive options for detection of HPV in cervical samples. Linear array enables the identification of the genotype present in the sample and the presence of multiple infections.

Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes.

Human papillomavirus (HPV) is a causal agent of cervical cancer, and persistent HPV16 or HPV18 infection carries a particularly high risk. The cobas HPV Test (cobas) provides individual HPV16/HPV18 genotyping with a simultaneous result for 12 other high-risk HPV (hrHPV) genotypes. Its analytical performance for hrHPV genotype detection was retrospectively evaluated against the digene Hybrid Capture 2 HPV DNA test (HC2), in three European centers, in 1360 cervical samples. Both HPV tests performed similarly, with no significant difference in the number of positive and negative samples identified by each test and good agreement between the tests was observed. Discordant samples were analyzed with the Linear Array HPV genotyping test. More low-risk HPV (lrHPV) genotypes were detected in HC2-positive/cobas-negative samples compared with HC2-negative/cobas-positive samples. Conversely, more hrHPV genotypes were detected in HC2-negative/cobas-positive samples compared with HC2-positive/cobas-negative samples. Eight HC2-negative/cobas-positive samples were positive for HPV16 compared with five HC2-positive/cobas-negative samples; HPV18 was detected in one HC2-negative/cobas-positive sample and one HC2-positive/cobas-negative sample. The cobas HPV Test demonstrates comparable analytical performance to the HC2 test, but with a lower rate of cross-reactivity with lrHPV genotypes, and has the advantage of simultaneously providing HPV16/HPV18 identification.